VHL inactivation in renal cell carcinoma: implications for diagnosis, prognosis and treatment.
about
VHL type 2B mutations retain VBC complex form and functionIdentifying mRNA targets of microRNA dysregulated in cancer: with application to clear cell Renal Cell Carcinoma.Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions.VHL and PTEN loss coordinate to promote mouse liver vascular lesions.Systematic Analysis of the Expression of the Mitochondrial ATP Synthase (Complex V) Subunits in Clear Cell Renal Cell Carcinoma.Pharmacological HIF2α inhibition improves VHL disease-associated phenotypes in zebrafish model.MicroRNA target site polymorphisms in the VHL-HIF1α pathway predict renal cell carcinoma risk.VHL Type 2B gene mutation moderates HIF dosage in vitro and in vivo.Molecular genetics of hereditary renal cancer: new genes and diagnostic and therapeutic opportunities.Clinical experience and critical evaluation of the role of sorafenib in renal cell carcinoma.Human monoclonal antibodies targeting carbonic anhydrase IX for the molecular imaging of hypoxic regions in solid tumours.Proliferation inhibition and the underlying molecular mechanisms of microRNA-30d in renal carcinoma cells.Strategies for the identification of ubiquitin ligase inhibitors.Progress and contrasts of the development of tivozanib for therapy of kidney cancer.The epigenetics of renal cell tumors: from biology to biomarkers.The role of the ubiquitin-proteasome system in kidney diseases.PDZK1 inhibits the development and progression of renal cell carcinoma by suppression of SHP-1 phosphorylation.Overexpression of Csk-binding protein contributes to renal cell carcinogenesis.Imaging-genomic pipeline for identifying gene mutations using three-dimensional intra-tumor heterogeneity features.Analysis of mTOR inhibition-involved pathway in ovarian clear cell adenocarcinoma.ActiveDriverDB: human disease mutations and genome variation in post-translational modification sites of proteins.The expression of RNA-binding protein RBM38 decreased in renal cell carcinoma and represses renal cancer cell proliferation, migration, and invasion.
P2860
Q21144205-834E4CA5-87BC-4437-AC5E-BA91981E415AQ33565049-E25CD2F2-0E43-49A8-940B-E916A2F25CC7Q33770680-5F8708B5-CFC9-4441-9D3D-4115CA2CDB24Q33862155-9252F1F3-08A0-48A1-96F7-6B17CBC6F8B3Q33869708-E23DA2C1-6471-4324-9219-A27D90FDB512Q35719850-CC2928E1-1D64-4E47-BC11-76641DF2F387Q36179757-7F0FA8BB-8568-4A72-ABE8-7DC200C72112Q37154944-D69EAB79-18D3-4A7F-8D99-5DA770DB35DBQ37183447-DAC23184-5184-401C-ADE5-852453EDB9B1Q37283736-20E69955-FB47-404B-BF12-90B9EDB7507DQ37330712-3F623D5F-7AE9-4FCE-9A19-940E6A8AF9E6Q37575126-D8C67BAA-50DD-4BE7-9AC5-F0D4F18C41E7Q37674741-E9EC9F79-80E1-489F-A68A-C3578922DF38Q37958038-1C5A8366-302B-44A7-9B2D-91C74AFF5A9FQ38016153-917B9000-C12C-49B8-A4ED-4CC226CBFD9FQ38017592-4EEDF503-9855-42B0-B4B4-BC1341E547C6Q38686603-804D34D8-8FB6-4B7E-BC75-B94CE160FD71Q39828303-EBB9E4EC-ACD8-44E9-A2DA-D689C8B8AFFBQ40028818-E04CA0C7-3DA3-47E4-AB13-09D6CC9D4932Q41895705-FAA07C6D-C9CF-4E2E-86E9-3FE98C828A01Q47150811-B91CBC42-B00F-48F1-A82F-2002FA8AB94AQ50687498-A44C5363-AE8C-42CE-AD6E-4975D33D8992
P2860
VHL inactivation in renal cell carcinoma: implications for diagnosis, prognosis and treatment.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
VHL inactivation in renal cell ...... osis, prognosis and treatment.
@en
VHL inactivation in renal cell ...... osis, prognosis and treatment.
@nl
type
label
VHL inactivation in renal cell ...... osis, prognosis and treatment.
@en
VHL inactivation in renal cell ...... osis, prognosis and treatment.
@nl
prefLabel
VHL inactivation in renal cell ...... osis, prognosis and treatment.
@en
VHL inactivation in renal cell ...... osis, prognosis and treatment.
@nl
P2860
P356
P1476
VHL inactivation in renal cell ...... osis, prognosis and treatment.
@en
P2093
Shufen Chen
W Kimryn Rathmell
P2860
P356
10.1586/14737140.8.1.63
P577
2008-01-01T00:00:00Z